Capital and Funding for Healthcare and Mission-Driven Work (Part 1 of 2): Beyond VCs

By: Ilya Ilienko, MBA, CMA, CPA

Healthcare is one of the few sectors where multiple capital models and legal structures can pursue the same mission — at the same time.  Venture-backed and traditional startups, non-profits, and hybrids often operate side-by-side, solving the same problem through different incentive structures, risk profiles, and time horizons. However, many non-profit models aside from healthcare may benefit from these hybrid-non-profit-profit approaches.

The same mission, under two roofs: a non-profit and a for-profit. The same unmet healthcare, or other needs under those roofs: novel service offerings and product deliveries, memory care and Alzheimer’s prevention, patient accessibility, subgroup or demographic-specific problem-solutions, clinical workflow inefficiency, and community health outcomes — can all be accessed and can take route through varying but similar means.

Depending on its form — for-profit, non-profit, or even hybrid — a healthcare company can seek funds from: donors, venture-capital groups, a non-profit research institute, a hospital, or a higher education-affiliated foundation, or a hybrid structure combining elements of all three — it really depends on its position.

Healthcare is an excellent industry example where both for-profit and a non-profit strategies can live well in the same conversation. What changes is not the mission-related problem but the vantage point, available tools, and how the organization goes about conducting its operations. What changes is the approach to how the company is formed, who controls the outcomes, how risk is tolerated, and how much time and capital the organization ultimately needs. In healthcare, capital funding and operations is not merely a financing decision — it is a governance decision, a mission decision, and often a values decision with legal consequences.

Why Healthcare and Non-Profit Funding is Different

Most startup capital frameworks assume flexible and adjustable runway and production speeds. In many industries, startups have flexibility afforded due to options that exist in sourcing, location, channels of delivery, and many other factors. Similarly, many startups expect rapid feedback-adjustment loops. Healthcare breaks all these notions.

Healthcare organizations typically operate under longer feedback and adjustment cycles; as such this has an impact on the timing of business model validation, production timing, and product or service adoption. Healthcare encompasses heavy regulatory oversight that can exist on local, state, and federal levels. At the same time, the ethical and reputational constraints create a much narrower road of travel for healthcare companies as opposed to startups in other industries. The risk model is steep, and the consequences extend beyond the business to real lives and patient well-being. The tension between outcomes and profitability is asymmetrical in healthcare and requires much more proactive management and hands-on stewardship.

As a result, capital in healthcare does more than just fund growth — its sources and surrounding decisions can heavily influence company trajectory and behavior.

A traditional capital source optimized for 5–7 year exits may force the company in the position of distorted clinical priorities that are forced by an external hand with its different horizon of priorities. Conversely, a steady and allocated stream of capital optimized for permanence may limit company innovation and slow down speed of its mission if governance and incentives are poorly designed.

This is why strategic capital architecture should influence/drive healthcare, as opposed to short-term driven capital events and options.

The Healthcare Capital Stack Beyond VC

Venture capital plays a large role in healthcare — but it occupies just one layer of a much broader option architecture/stack.

1. Venture Capital — aggressive, dynamic, fast to the market and fast to results

VC and private firms that manage the wealth of ultra-high-net-worth individuals or families often invest in for-profit healthcare startups. This market for healthcare may work best when the model is more apt to scale, similar to mainstream industry startups. Think health-tech services, platforms, analytics, AI integration and new capability introductions. VCs and healthcare pair well when marginal costs of revenue decline with growth, similar to traditional startup scaling environment. The more regulatory risk, oversight, and the number of unknowns, the less VC options tend to exist.

If these conditions fit the business model, then bringing on a VC can increase execution speed, bring muscle — talent density, and provide a level-up in networking and visibility. But at the same time, VCs also exert pressure and shift governance. Venture capital does not fund non-profits; it funds outcomes aligned with goals, liquidity needs, and provides active oversight — and as such immediately puts the company on a different and much more dynamic playing field.

In this category, disciplined financial reporting and consistent delivery are critical.

2. Strategic Corporate Capital

Large market participants often invest not just for returns, but for market access, shared learning, technological exposure, and mission alignment. Corporate capital can be accessible from both non- and for-profit lenses, but tends to favor the for-profit set up.

Health insurers, consumer brands, and hospital systems frequently support startups to pilot solutions, accelerate adoption, expand service offerings, capture market share, and increase visibility. Corporate capital carries well known names such as HCA Healthcare, Humana, Procter & Gamble, IBM, and many others that come in contact with healthcare through access, services, products, and technology. These types of organizations have historically partnered with healthcare and medical research to bridge industry, academia, and technical innovation.

Strategic corporate capital often values long-term alignment over short-term multiples, giving runway length flexibility. Additionally, another attractive market entry point into corporate capital is the typical risk categories reserved for allocating funding. For example, funding can be set aside as 10% reserved for high-risk investment, 40% medium-risk projects, and 50% low-risk allocation. This is where your mission’s “story” matters, a higher-risk but a unique and attractive proposition can unlock funds otherwise not available through VCs or other sources for example.

In this category unique story will help overcome competitiveness.

3. Grants and Non-Dilutive Capital

Both healthcare for-profit and non-profit are uniquely positioned to look into: grants, foundations, and research-driven funding programs. Federal grants can even issue funds for “high-risk — high-reward” projects. The primary federal grant programs, which include SBIR/STTR, have issued more than $5B of funding every year through agencies like NIH. Other granting agencies exist as well, such as ARPA-H/AHRQ. These programs assist for-profit and non-profit, as well as academic institutions and a blend-thereof.

Startups in healthcare can also take advantage of private grants and foundation capital. For example The Gates and The Rockefeller foundations fund scalable healthcare oriented initiatives. Switzerland’s Future of Health Grant is a program that just recently opened in 2026, which has a focus on digital health for telemedicine, patient analytics tools, and digitally driven therapeutics, among many others. This and similar international initiatives highlight how digital health is attracting targeted grant capital globally.

Grants preserve equity and reduce financial pressure — but they introduce oversight and focus risk, reporting burdens and overhead, and constrained and often segregated use of funds. Non-dilutive does not mean non-strategic no-strings-attached. Further, just like other programs, these are highly competitive and can benefit greatly from a seasoned “story-teller” and company position.

Navigating the grant and foundation landscape takes patience and knowhow to identify sources, navigate the application process, and ongoing compliance, all of which is typically burdensome.

4. Alternative Ecosystem Financing Alliances, Accelerators, and “Connectors”

Academia and University-affiliated programs, such as the Cedars-Sinai, NYU, often provide seed funding, mentorship, and lab space or in-house expertise in exchange for a small equity stake, preferential future terms and benefits, and/or branded research collaboration i.e. licensing agreements.

Another plus is that many reputable universities have dedicated venture capital funds and networks that provide access to capital to promising startups. These academia and research program channels also have resources and knowhow to jointly apply for large federal grants, such as those from the NIH or NSF, which often look favorably on academic-industry partnerships. If the grant is awarded to the university, a portion of the funds may be sub-granted to the startup to perform specific parts of the R&D work.

Last important note on these channels — these ecosystems often unlock opportunities that are unavailable through capital markets alone. Think brand name weight behind you, reputation, legacy knowledge and experience, keys to open doors and make introductions. The articulation of your startup mission, potential, and industry position is of utmost importance in this space.

5. Local, State, and Federal Tax Programs

Certain federal and state R&D and other tax credit programs exist where startups can recover a percentage of their qualifying research and development expenses, including opening up offices and official domiciles, hiring talent, and other mission-critical initiatives. R&D has been a lucrative credit in the past and can prove to be generous on both federal and state levels, depending on where you are, but can be well worth the compliance and filing.

Other programs exist on the federal and on many state levels, and can provide tax relief for the actual cost of establishing a physical facility or office lease, including paying wages, and setting up infrastructure. A few well-known ones include: Maryland’s Biotechnology Investment Incentive Tax Credit, Massachusetts’ Life Science Center tax incentive program, and Texas with its newly expanded R&D competitiveness as of Jan. 2026.

This discussion sets the stage for how healthcare and mission-driven organizations position themselves to access capital.

In part 2, we’ll shift from capital sources to organizational choices — when non-profit structures outperform for-profit startups, how hybrid models work in practice, the governance tradeoffs they introduce, and real-world examples and observations from operating inside these environments. We’ll also touch on operator-experience, governance-awareness, and organization-level application. As in this piece, a heavy healthcare element will be present.